Patents Assigned to Assistance Publique-Hopitaux De
-
Publication number: 20220119886Abstract: The application relates to means for diagnosing, predicting or monitoring Pneumocystis pneumonia (PCP). The means of the application are also suitable for determining or predicting the efficacy of a drug or treatment against PCP in a human patient. The means of involve the detection and/or quantification, more particularly the quantification, of the RNA transcripts of two different P. jirovecii mitochondrial genes. The first of said two P. jirovecii mitochondrial genes is the P. jirovecii gene, the sequence of which codes for the Cytb protein or the P. jirovecii mitochondrial Small Sub-Unit (mtSSU) gene. The second of said two P. jirovecii mitochondrial genes is a P. jirovecii gene, the sequence of which transcribes into a P. jirovecii ribosomal RNA, e.g., be the mitochondrial P. jirovecii Large Sub-Unit (mtLSU) gene.Type: ApplicationFiled: December 15, 2021Publication date: April 21, 2022Applicants: INSTITUT PASTEUR, ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS, UNIVERSITE PARIS DIDEROT - PARIS 7Inventors: Alexandre ALANIO, Stephane BRETAGNE, Francoise DROMER, Aude STURNY-LECLERE, Benjamin HOMMEL, Marion BENAZRA
-
Patent number: 11300569Abstract: The present invention relates to the prognosis of the outcome of a cancer in a patient, which prognosis is based on the quantification of one or several biological markers that are indicative of the presence of, or alternatively the level of, the adaptive immune response of said patient against said cancer.Type: GrantFiled: December 14, 2018Date of Patent: April 12, 2022Assignees: ISERM (Institut National de la Santé et de la Recherche Médicale), Université Paris Descartes, Assistance Publique-Hôpitaux de Paris (APHP)Inventors: Jerome Galon, Franck Pages, Wolf-Herman Fridman
-
Publication number: 20220096486Abstract: The present invention relates to compounds and compositions comprising said compounds, for use in the treatment of ADCY5-related dyskinesia.Type: ApplicationFiled: March 24, 2020Publication date: March 31, 2022Applicant: ASSISTANCE PUBLIQUE - HOPITAUX DE PARISInventors: Aurélie MENERET, Emmanuel FLAMAND-ROZE, Louise-Laure MARIANI
-
Publication number: 20220096452Abstract: A local anesthetic chosen from the group of amino amide or amino ester, and a composition or pharmaceutical composition including the local anesthetic. The local anesthetic is for use in the treatment of neurological symptoms resulting from brain dysfunctions such as motor, cognitive, sensory, visual deficits, and/or apathetic, catatonic, vegetative and/or minimally conscious states.Type: ApplicationFiled: January 22, 2020Publication date: March 31, 2022Applicants: ICM (INSTITUT DU CERVEAU ET DE LA MOELLE ÉPINIÈRE), ASSISTANCE PUBLIQUE HOPITAUX DE PARIS, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), SORBONNE UNIVERSITEInventors: Laurent COHEN, Randa EL HACHEM, Piirika CREPIN, Guillaume GUERINEAU DE LAMERIE, Gérard SYLVESTRE
-
Publication number: 20220079507Abstract: A system to measure and monitor neurodegeneration of a subject, which includes: an acquisition module configured to acquire electroencephalographic signals with multiple EEG channels from a subject perceptually isolated; a calculation module configured to extract at least one EEG metric representative of neurodegeneration; and an evaluation module configured to evaluate the at least one EEG metric and extract a neurodegeneration index.Type: ApplicationFiled: December 20, 2019Publication date: March 17, 2022Applicants: ICM (INSTITUT DU CERVEAU ET DE LA MOELLE ÉPINIÈRE), INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, APHP (ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS), SORBONNE UNIVERSITÉInventors: Stephane EPELBAUM, Sinead GAUBERT, Federico RAIMONDO, Jacobo D SITT, Lionel NACCACHE
-
Patent number: 11261445Abstract: Cystic fibrosis (CF) is a genetic disease caused by mutations in the gene encoding the 5 CFTR Cl— channel and affects several organs, but the most severe consequences are observed in the lung. The inventors have now instigated the combination of Orkambi® and ANO1 TSB (SEQ ID NO:1) and show that said combination increases mucociliary clearance and chloride channel activity. Thus the combination represents an alternative treatment for CF subjects.Type: GrantFiled: October 16, 2018Date of Patent: March 1, 2022Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), SORBONNE UNIVERSITE, ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS (APHP)Inventors: Olivier Tabary, Florence Sonneville, Harriet Corvol
-
Patent number: 11246525Abstract: A method for quantifying the balance of an individual includes segmenting, as a function of time, a statokinesigram(s) of an individual so as to generate several statokinesigram portions; extracting, from the statokinesigram portions, values of at least one trajectory parameter; determining the value of at least two quantifiers, from the values of trajectory parameters extracted in the extraction step, for each of the statokinesigram portions generated in the segmentation step; and determining said value representative of the balance of the individual from the values of the quantifiers of each of the statokinesigram portions. The method may be implemented by a processor and memory.Type: GrantFiled: November 16, 2018Date of Patent: February 15, 2022Assignees: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, ETAT FRANCAIS—MINISTERE DE LA DEFENSE—DIRECTION CENTRALE DU SERVICE DE SANTE DES ARMEES, ECOLE NORMALE SUPERIEURE PARIS-SACLAY, UNIV PARIS XIII PARIS-NORD VILLETANEUSE, UNIVERSITE DE PARISInventors: Nicolas Vayatis, Pierre Paul Vidal, Julien Audiffren, Alain Yelnik, Damien Ricard, Ioannis Bargiotas, Laurent Oudre, Stéphane Buffat
-
Publication number: 20220039736Abstract: The invention relates to modulating epileptogenicity in a brain of an epileptic patient. The method according to the invention comprises the steps of: providing a virtual brain; providing a model of an epileptogenic and of a propagation zones and loading said models in the virtual brain to create a virtual epileptic brain; acquiring data of the brain of the epileptic patient; identifying, in said data, a location of at least one possible epileptogenic zone; fitting the virtual epileptic brain against the data acquired from the epileptic patient and parametrizing said at least one possible epileptogenic zone in the virtual epileptic brain as an epileptogenic zone; and simulating, within the virtual epileptic brain, the effect of a network modulation mimicking a clinical intervention of the brain of the patient.Type: ApplicationFiled: October 25, 2021Publication date: February 10, 2022Applicants: UNIVERSITE D'AIX MARSEILLE (AMU), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), ASSISTANCE PUBLIQUE - HOPITAUX DE MARSEILLE (AP-HM), INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)Inventors: Viktor Jirsa, Christophe Bernard, Fabrice Bartolomei, Maxime Guye
-
Publication number: 20220042016Abstract: The present invention concerns the V617F variant of the protein-tyrosine kinase JAK2, said variant being responsible for Vaquez Polyglobulia. The invention also relates to a first intention diagnostic method for erythrocytosis and thrombocytosis allowing their association with myeloproliferative disorders, or to the detection of the JAK2 V617F variant in myeloproliferative disorders allowing their reclassification in a new nosological group.Type: ApplicationFiled: September 29, 2021Publication date: February 10, 2022Applicants: Institut Gustave-Roussy, Institut National de la Sante et de la Recherche Medicale (INSERM), Assistance Publique - Hopitaux de Paris, Universite de Versailles - St Quentin en Yvelines, Universite Paris - SUDInventors: William VAINCHENKER, Valerie UGO, Chloe James, Jean-Pierre LE COUEDIC, Nicole CASADEVALL
-
Patent number: 11242564Abstract: The present invention relates to a method for predicting the survival time of a patient suffering from a solid cancer comprising i) determining in a tumor sample obtained from the patient the gene expression level of at least 7 genes selected from the group consisting of CCR2, CD3D, CD3E, CD3G, CD8A, CXCL10, CXCL11, GZMA, GZMB, GZMK, GZMM, IL15, IRF1, PRF1, STAT1, CD69, ICOS, CXCR3, STAT4, CCL2, and TBX21, ii) comparing every expression level determined at step i) with their predetermined reference value and iii) providing a good prognosis when all expression levels determined at step i) are higher than their predetermined reference values, or providing a bad prognosis when all expression levels determined at step i) are lower than their predetermined reference values or providing an intermediate prognosis when at least one expression level determined value is higher than its predetermined value. The method is also particularly suitable for predicting the responsiveness of the patient to a treatment.Type: GrantFiled: July 12, 2013Date of Patent: February 8, 2022Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE DE PARIS, ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS (APHP)Inventors: Jerome Galon, Franck Pages, Bernard Mlecnik, Gabriela Bindea
-
Patent number: 11229356Abstract: Evaluation of the perception of colors by mammals with a view to obtaining a characteristic biomarker of each tested subject takes advantage of the slow pupillary oscillatory response to generate an objective neurological signature of this perception of colors. A method based on pupil frequency tagging is used at a tagging frequency Ftag adapted to the pupil response speed. A dynamic two-color stimulus is displayed, this stimulus comprising a two-color pattern the colors of which are inverted at the frequency Ftag, one of the colors gradually varying in a range of possible values. From the pupillary response, a signal representative of the oscillation power of the pupil is generated. The minimum of this signal corresponds to the relative iso-luminance of the tested pair of colors.Type: GrantFiled: March 29, 2018Date of Patent: January 25, 2022Assignees: INSTITUT DU CERVEAU ET DE LA MOELLE EPINIERE (ICM), CENTRE NATIONAL DE LA RACHERCHE SCIENTIFIQUE (CNRS), INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS (AP-HP), SORBONNE UNIVERSITEInventors: Pierre Pouget, Pierre Daye, Jean Lorenceau
-
Patent number: 11231422Abstract: Plasma levels of different sub-populations of microvesicles (endothelial, leukocyte, platelet and hepatocyte) were measured by flow cytometry or ELISA/filtration on blood samples from 125 patients with cirrhosis, for which 36 of them were diagnosed with HCC at inclusion. The inventors show that the levels of microvesicles of endothelial origin (CD62E+) could predict the occurrence of HCC in patients with cirrhosis. Therefore the present invention relates to a method for determining whether a patient suffering from cirrhosis is at risk of having or developing hepatocellular carcinoma comprising determining the level of endothelial-derived microvesicles (e.g. by flow cytometry) in a blood sample obtained from the patient.Type: GrantFiled: March 20, 2018Date of Patent: January 25, 2022Assignees: INSERM (Institut National de la Santé et de la Recherche Médicale), Université Paris Descartes, Assistance Publique Hôpitaux de Paris (APHP), UniversitéParis Diderot—Paris 7Inventors: Pierre-Emmanuel Rautou, Chantal Boulanger-Robert
-
Publication number: 20220011217Abstract: A method for determining at least one protein in the blood which is more precise while still being simple to implement. The method exploits in an original way the spectroscopy and the dosing techniques to determine accurately the content in proteins of the biological sample, notably for oxyhemoglobin, methemoglobin, heme bound to serum albumin and hemopexin and bilirubin. Such method can advantageously be used in various applications concerning heme-related or hemoprotein-related disorders, notably method for diagnosing, for following a treatment, for determining biomarkers or for screening. Such a method is also interesting for qualifying blood bags.Type: ApplicationFiled: November 29, 2019Publication date: January 13, 2022Applicants: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITÉ PARIS EST CRÉTEIL VAL DE MARNE, ASSISTANCE PUBLIQUE - HOPITAUX DE PARISInventors: Laurent KIGER, Pablo BARTOLUCCI, Michael MARDEN
-
Publication number: 20220008372Abstract: Methods of administering compounds of Baclofen and pharmaceutically acceptable salts thereof, or a composition comprising such a compound, are provided for topical treatment and prevention of localized musculoskeletal pain.Type: ApplicationFiled: October 29, 2019Publication date: January 13, 2022Applicant: ASSISTANCE PUBLIQUE - HOPITAUX DE PARISInventor: Céline Greco
-
Patent number: 11219683Abstract: Methods and compositions are provided that can be used to vaccinate against and treat HIV. Specifically contemplated are vaccine compositions and methods of using these compositions treat HIV in patients. Aspects of the disclosure relate to an anti-CD40 antibody-HIV antigen fusion protein comprising (i) an anti-CD40 heavy chain (HCD40)-HIV antigen (Ag) fusion protein comprising the formula: HCD40-Ag, wherein Ag is a polypeptide with at least 80% sequence identity to SEQ ID NO:1; and (ii) an anti-CD40 light chain (LCD40).Type: GrantFiled: June 19, 2020Date of Patent: January 11, 2022Assignees: INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE M{circumflex over (D)}DICALE (INSERM), UNIVERSITE PARIS EST CRETEIL VAL DE MARNE, ASSISTANCE PUBLIQUE HOPITAUX DE PARIS, BAYLOR RESEARCH INSTITUTEInventors: Yves Levy, Gerard Zurawski, Sandra Zurawski, Anne-Laure Flamar
-
Patent number: 11202826Abstract: The present application relates to a method for desensitization of allergic patients. More specifically it relates to an epicutaneous desensitization method, applicable to any type of allergens and of patients. The method of the invention is essentially non-invasive and does not require the use of adjuvants. Further, it may be easily applied and monitored by the actual patient.Type: GrantFiled: July 23, 2020Date of Patent: December 21, 2021Assignees: DBV Technologies, Assistance Publique-Hôpitaux De Paris, Université De ParisInventors: Christophe Dupont, Pierre-Henri Benhamou, Bertrand Dupont
-
Patent number: 11203788Abstract: The present invention concerns an in vitro method for diagnosing a myeloid tumour or a lymphoid tumour in a subject, which comprises the step of analyzing a biological sample from said subject by (i) detecting the presence of a mutation in the Ten Eleven Translocation protein family member 2 gene (TET2) coding for the polypeptide having the sequence SEQ ID NO: 2, and/or (ii) analyzing the expression of the TET2 gene; wherein the detection of such a TET2 mutation, of the absence of expression of TET2 or of the expression of a truncated TET2 is indicative of a subject developing or predisposed to develop a myeloid tumour or a lymphoid tumour.Type: GrantFiled: April 8, 2020Date of Patent: December 21, 2021Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), INSTITUT GUSTAVE-ROUSSY, ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS, CENTRE HENRI BECQUEREL, UNIVERSITE PIERRE ET MARIE CURIE, UNIVERSITE PARIS-SUDInventors: Franck Viguie, Olivier Bernard, Michaela Fontenay, Christian Bastard, Francois Delhommeau, William Vainchenker
-
Patent number: 11162100Abstract: The present invention concerns the V617F variant of the protein-tyrosine kinase JAK2, said variant being responsible for Vaquez Polyglobulia. The invention also relates to a first intention diagnostic method for erythrocytosis and thrombocytosis allowing their association with myeloproliferative disorders, or to the detection of the JAK2 V617F variant in myeloproliferative disorders allowing their reclassification in a new nosological group.Type: GrantFiled: January 6, 2020Date of Patent: November 2, 2021Assignees: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS, INSTITUT NATIONAL DE LA SANTE DE LA RECHERCHE MEDICALE (INSERM), INSTITUT GUSTAVE-ROUSSY, UNIVERSITE DE VERSAILLES-ST QUENTIN EN YVELINES, UNIVERSITE PARIS-SUDInventors: William Vainchenker, Valerie Ugo, Chloe James, Jean-Pierre Le Couedic, Nicole Casadevall
-
Publication number: 20210315507Abstract: A method for the generation of a consciousness indicator for a non-communicating subject, including generating a sensory stimulation involving at least one of the five senses, the sensory stimulation having multiple consecutive stimuli including at least a first stimulus and a second stimulus relating to the same sense and different from one another, measuring an electrocardiographic signal of the subject during the generation of the sensory stimulation, extracting at least one EKG feature from the electrocardiographic signal associated to cognitive processes and generating a consciousness indicator using the EKG features as input of a classifier.Type: ApplicationFiled: September 11, 2019Publication date: October 14, 2021Applicants: ICM (INSTITUT DU CERVEAU ET DE LA MOELLE ÉPINIÈRE), INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, APHP (ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS), SORBONNE UNIVERSITÉInventors: Federico RAIMONDO, Jacobo D SITT, Lionel NACCACHE, Diego FERNANDEZ SLEZAK
-
Publication number: 20210301344Abstract: The present application describes and claims a novel method for identifying and stratifying the risk of developing a BK virus nephropathy (“Nx BK-v” below) in patients having undergone a kidney transplant. This method uses an index combining at least three bio-markers: i) the intensity of the anti-BK-v memory T lymphocyte response (memory T lymphocytes which are specific to v, hereinafter “LTm anti-BK-v”), ii) the number of occurrences of incompatibility in the HLA alleles of class I and class II between the donor and the recipient of the graft, taking into account iii) the viral charge of the BK-v virus in the whole blood of the patient. The present method allows a very precise evaluation of the risk of developing an Nx BK-v during the months following the test with the aim of optimising the immuno-suppressive treatment in order to better preserve the transplanted kidney.Type: ApplicationFiled: June 18, 2019Publication date: September 30, 2021Applicants: UNIVERSITE PARIS-SACLAY, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), ASSISTANCE PUBLIQUE - HOPITAUX DE PARISInventors: Yassine TAOUFIK, Antoine DURRBACH, Manon DEKEYSER